One concern is that Set is used for weight loss only in patients with mutations in the POMC/leptin/MC4R pathways (50, 52–54), but not in the most common polygenic form of obesity. The gene discussed is POMC; the disease is obesity due to melanocortin 4 receptor deficiency.